<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6621">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02008903</url>
  </required_header>
  <id_info>
    <org_study_id>07-0223</org_study_id>
    <secondary_id>FD-R-G04086-01</secondary_id>
    <nct_id>NCT02008903</nct_id>
  </id_info>
  <brief_title>Esophageal String Test in Eosinophilic Esophagitis</brief_title>
  <official_title>Phase 2 Study of Esophageal String Test in Diagnosing Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to develop a novel minimally invasive device, the
      Esophageal String Test (EST) to monitor esophageal inflammation during treatment of the rare
      disease Eosinophilic Esophagitis (EoE) in a safe and efficacious manner.

      This study is broken down into 2 specific aims:

      Specific Aim 1: Identify the EoE Biomarker Panel (EBP) that will improve the sensitivity and
      specificity of the EST for documenting esophageal inflammation in a 1-hour time point.

      Specific Aim 2: Validate the ability of the EST EBP to monitor therapeutic efficacy in a
      1-hour sampling time.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>association of biomarker levels in biopsy tissue with pathological findings (eosinophil counts)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation for the level of each biomarker between EST and tissue biopsy samples</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>ability of an individual biomarker (or combination of biomarkers) to differentiate mucosal biopsy EBP sample obtained before and after treatment</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>ability of an individual biomarker (or combination of biomarkers) to differentiate post-treatment mucosal biopsy EBP sample from normal control</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>EoE active disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>EoE remission</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>normal control</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Any pediatric or adult patient undergoing a clinically indicated endoscopy with biopsy at
        a participating site may be recruited. (initial cohort)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing esophagogastroduodenoscopy (EGD) at Children's Hospital
             Colorado or participating site in whom an inflammatory GI disease is suspected may be
             asked to enroll.

          -  Patients with symptoms of abdominal pain, vomiting, growth delay, or malabsorption
             for which an etiology has not been determined are typical patients for enrollment.

          -  Patients with chronic eosinophilic esophagitis (EoE) in whom symptoms suggest ongoing
             inflammation will also be recruited.

        Exclusion Criteria:

          -  Patients suffering from bleeding diathesis, or any other comorbid condition which
             their doctor feels may put them at additional risk will be excluded.

          -  Patients will also be excluded if they have a family history of connective tissue
             disease.

          -  In addition, if the patient is undergoing a therapeutic endoscopy (such as
             dilatation, sclerotherapy, variceal banding), they will not be enrolled.

          -  Patients will be excluded if they have a history of esophageal stricture or surgery
             such as fundoplication, if they are allergic to gelatin, or are unable to swallow
             pills.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn T Furuta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Colorado</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy M Moore, MPH</last_name>
      <phone>720-777-4800</phone>
      <email>wendy.moore2@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Glenn T Furuta, MD</last_name>
      <phone>720-777-7457</phone>
      <email>glenn.furuta@childrenscolorado.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paul Menard-Katcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Amsden</last_name>
      <phone>312-227-3524</phone>
      <email>kamsden@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Amir F Kagalwalla, MBBS</last_name>
      <email>akagalwalla@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amir F Kagalwalla, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelika Zalewski</last_name>
      <phone>312-695-4054</phone>
      <email>angelika.zalewski@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ikuo Hirano, MD</last_name>
      <email>i-hirano@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ikuo Hirano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Furuta GT, Kagalwalla AF, Lee JJ, Alumkal P, Maybruck BT, Fillon S, Masterson JC, Ochkur S, Protheroe C, Moore W, Pan Z, Amsden K, Robinson Z, Capocelli K, Mukkada V, Atkins D, Fleischer D, Hosford L, Kwatia MA, Schroeder S, Kelly C, Lovell M, Melin-Aldana H, Ackerman SJ. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut. 2013 Oct;62(10):1395-405. doi: 10.1136/gutjnl-2012-303171. Epub 2012 Aug 15.</citation>
    <PMID>22895393</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 11, 2013</lastchanged_date>
  <firstreceived_date>December 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
